Study Summary
This trial is testing a new drug, epcoritamab, to see if it is safe and effective in treating B-cell Non-Hodgkin Lymphoma.
- Follicular Lymphoma
- Non-Hodgkin's Lymphoma
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
11 Primary · 48 Secondary · Reporting Duration: From 6 weeks after enrollment until treatment discontinuation, assessed up to 3 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
12 Treatment Groups
Arm 10 - Epcoritamab + R-ICE
1 of 12
Arm 9 - Epcoritamab + Lenalidomide
1 of 12
Arm 6 - Epcoritamab + R- Lenalidomide
1 of 12
Arm 2 - Epcoritamab + R- Lenalidomide
1 of 12
Arm 1 - Epcoritamab + R-CHOP
1 of 12
Arm 2 - Epcoritamab + R2
1 of 12
Arm 3 - Epcoritamab + BR
1 of 12
Arm 4 - Epcoritamab + R-DHAX/C
1 of 12
Arm 5 - Epcoritamab + GemOx
1 of 12
Arm 6 - Epcoritamab + R2
1 of 12
Arm 7 - Epcoritamab maintenance
1 of 12
Arm 8 - Epcoritamab + R mini-CHOP
1 of 12
Experimental Treatment
662 Total Participants · 12 Treatment Groups
Primary Treatment: rituximab and lenalidomide · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- Falchi L, Offner F, Belada D, Brody J, Linton KM, Karimi Y, Cordoba R, Snauwaert S, Abbas A, Wang L, Wu J, Elliott B, Clausen MR. ABCL-452 First-Line Treatment With Subcutaneous Epcoritamab + R-CHOP in Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Phase 1/2 Data Update. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S380. doi: 10.1016/S2152-2650(22)01542-7.
- Brody J, Wahlin BE, Phillips T, Costello R, Lugtenburg P, Cordoba R, Wang L, Wu J, Elliott B, Abbas A, J Rgensen J. ABCL-439 Subcutaneous Epcoritamab With Gemcitabine + Oxaliplatin (GemOx) Induced High Response Rates in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Ineligible for Autologous Stem Cell Transplant (ASCT). Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S379-S380. doi: 10.1016/S2152-2650(22)01541-5.
- Falchi L, Leppä S, Wahlin BE, Nijland M, Christensen JH, de Vos S, Holte H, Linton KM, Abbas A, Wang L, Dinh M, Elliott B, Belada D. IBCL-460 Subcutaneous Epcoritamab With Rituximab + Lenalidomide (R(2)) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S392. doi: 10.1016/S2152-2650(22)01565-8.
- 2020. "Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04663347.
Frequently Asked Questions
How many participants have been recruited for this clinical trial?
"The AbbVie-sponsored study requires 396 qualified participants, and will be conducted at the John Theurer Cancer Center in Hackensack, New Jersey as well as UMPC Hillman Cancer Center in Pittsburgh, Pennsylvania." - Anonymous Online Contributor
Are there still vacancies in this clinical trial?
"According to clinicaltrials.gov, the current state of affairs shows that this trial is actively seeking participants; it was first posted on November 16th 2020 and edited most recently on April 13th 2022." - Anonymous Online Contributor
How many centers are conducting this research trial?
"Patients interested in participating can find locations for this clinical trial at the John Theurer Cancer Center, Hackensack UMC (Hackensack NJ), UMPC Hillman Cancer Center cancer Pavillion (Pittsburgh PA) and Dana Farber Cancer Institute (Boston MA). 10 other sites are also available." - Anonymous Online Contributor
What medical conditions are commonly addressed with rituximab and lenalidomide?
"Rituximab and lenalidomide are typically used to treat macular edema, as well as pheochromocytomas, ocular conditions, and ulcerative colitis." - Anonymous Online Contributor
Are there any prior investigations that have combined rituximab and lenalidomide?
"Rituximab and lenalidomide were first studied at the NIH Clinical Centre on Rockville Pike back in 1993. To date, there have been 5624 studies that have concluded with 3255 presently ongoing; a substantial amount of these trials are taking place out of Hackensack, New Jersey." - Anonymous Online Contributor